TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06792903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG101 high dose + artificial tear
Description: Patient in this group received high dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive placebo CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG101 high dose + artificial tear
Description: Patient in this group received high dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive placebo CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG101 low dose + artificial tear
Description: Patient in this group received low dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive high dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CG101 low dose + artificial tear
Description: Patient in this group received low dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive high dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo + artificial tear
Description: Patient in this group received placebo dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive low dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + artificial tear
Description: Patient in this group received placebo dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive low dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
Study: NCT06793943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zasocitinib
Description: Zasocitinib tablets specified doses on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zasocitinib
Description: Zasocitinib tablets specified doses on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zasocitinib
Description: Zasocitinib tablets specified doses on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zasocitinib
Description: Zasocitinib tablets specified doses on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COC
Description: COC tablets (containing LNG and EE) specified doses on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets specified doses on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin tablets specified doses on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole tablets specified doses on specified days.
Study: NCT06796036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combat Medic Decision-Making with and without artificial intelligence assistance
Description: Participants will complete 10 simulated Tactical Combat Casualty Care (TCCC) scenarios, with 5 scenarios conducted using AI assistance (GPT-4) and 5 without AI. In AI-assisted scenarios, participants will use GPT-4 to query and optimize ventilator settings based on patient data, while non-AI scenarios rely solely on their clinical judgment.
Study: NCT06793306

Intervention type: OTHER
Intervention: Age
Description: Breast cancer patients were divided into young breast cancer and non-young breast cancer by age 35

Intervention type: OTHER
Intervention: combination therapy
Description: To observe and compare the difference in diagnosis, combined treatment and prognosis between young and non-young breast cancer
Study: NCT06796699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH56 Capsule
Description: GH56 capsule for oral administration at specified doses on scheduled days.
Study: NCT06796400

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General exercises
Description: 4 general exercises were done by control group with 10 repetitions and 3 sets, 6 times per week, up to 8 weeks.These exercises are for lower trapzius and serratus anterior mucles strengthing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theraband exerises
Description: 5 Thera-band exercises were completed by experimental group with 3 sets and 10 repetitions, 6 times per week, up to 8 weeks. These exercises are for lower trapzius and serratus anterior mucles strengthing.
Study: NCT06307652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg
Description: 1 capsule of balcinrenone/dapagliflozin 15 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg
Description: 1 capsule of balcinrenone/dapagliflozin 40 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin
Description: 1 tablet of dapagliflozin 10 mg and 1 capsule of matching placebo for balcinrenone/dapagliflozin once daily, oral use
Study: NCT06795607

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The experimental product is a dietary supplement manufactured by Cerbios-Pharma S.A, Each stick contains probiotic live cultures of Enterococcus lactis SF68® at a concentration of 10\^9 CFU, phytosterols, 6S-5MeTHF, maltose and silicon dioxide. Study participants will be given N°3 packs each containing 30 stick packs of 1.7 g each, in granulated form in sufficient quantity for the entire duration of the study (12 weeks). Subjects will be required to consume N°1 stick pack of the supplement daily after dinner for 12 continuous weeks. The product should be placed directly on the tongue and should be taken without water. After taking the product, the subject should drink half a glass of water to promote solubilization and transit. The supplement should be stored in a cool, dry place, away from light, moisture and direct heat sources to ensure the viability of the probiotic strain until the expiration date.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: N°1 stick/day of placebo food supplement (i.e., stick without added probiotics), with the same intake modalities as probiotic.
Study: NCT06797297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI363
Description: a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized monoclonal anti-PD1 antibody
Study: NCT06794697

Intervention type: OTHER
Intervention: Questionnaire including APAIS scale
Description: Patients will complete a questionnaire in two stages : upon admission and just before leaving for the operating room

Intervention type: OTHER
Intervention: Questionnaire including APAIS scale
Description: Patients will complete a questionnaire in two stages : upon admission and just before leaving for the operating room
Study: NCT06793826

Intervention type: BIOLOGICAL
Intervention: DTaP-IPV-Hep B-PRP-T combined vaccine
Description: prefilled syringe injection intramuscular
Study: NCT06796348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation alone
Description: RFA of a cancer in the thyroid gland.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Hemithyroidectomy of the thyroid lobe with cancer
Study: NCT05635396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable, non invasive sensor for seizure detection
Description: The device consists of a chest strap and an electronics module that attaches to the strap. The device stores and transmits vital sign data including ECG, heart rate, respiration rate, body orientation and activity. This sensor will be worn every day (on a 24 hours basis) excepted during weekends for up to 4 weeks.
Study: NCT05377450

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Engage Partial Knee
Description: Unicompartmental knee arthroplasty utilizing the Engage Partial Knee system with bone cement.
Study: NCT06797960

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra sound guided Injection of PRF intra articularly
Description: Intra articular injection of PRF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra articular injection of HA
Description: Intra articular injection of HA
Study: NCT06799689

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: esmadem education
Description: By providing information about Esma-i Husna, the journey of knowing oneself and character building with Esma-i Husna will be emphasized. It will be carried out with the aim of building on 99 names, namely Allah, Rahman and Rahim, and reducing depressive feelings by benefiting from the guidance of these names.In the second session, it will be explained through the names Esma-i Husna, Celal and Cemal in order to manage depressive feelings and contribute to positive coping. The togetherness of pain as well as happiness, ease along with difficulty, joy along with sadness in a balanced life will be discussed with the name Zü'l Celâl ve'l İkram and the study of Journey to perfection through the names Celal and Cemal. The meaning of existence and life in spirit will be discussed through the name Rab, the life cycle will be explained by establishing a relationship with the names Hafıd-Râfi, Kâbıd-Bâsıt, Muız-Müzil. In addition, it will be carried out within the framework of the name Hakim,
Study: NCT06798974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three-dimensional video
Description: Patients who meet the criteria for inclusion in the study will be randomly assigned to intervention and control groups. The intervention group will be shown a 3D lemon video with virtual reality glasses. The video will be created by a company that shoots 3D videos. Opinions of three experts will be obtained for the suitability of the video. The video will be shown to patients for 5 minutes. In order to control the effects that may arise from the practitioner during the study, the virtual reality glasses application will be applied to all patients by the same clinic nurse. The control group will not receive any intervention and will receive standard care. Data collection forms will be given to the patient by the researcher and will be collected after the patient fills them out.
Study: NCT06800274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAAGA (N-acetyl-aspartyl-glutamate) 49 mg/mL
Description: 80 patients were randomly assigned to NAAGA in single dose (49 mg/mL), instilled as 1 drop per eye four times daily for four weeks. Specific diagnostic tests and procedures for dry eye disease were performed at week 0 (baseline), week 2 and week 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine hydrochloride 0.05%
Description: 54 patients were randomly assigned to azelastine hydrochloride 0.05% instilled as 1 drop per eye 2 times a day in the conjunctival sac for for four weeks. Specific diagnostic tests and procedures for dry eye disease were performed at week 0 (baseline), week 2 and week 4.
Study: NCT06799026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Bispecific T-cell engager antibody, 1.9 and 1.1 mL vials, via subcutaneous (under the skin) injection per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Granulocyte-Macrophage Colony-Stimulating Factor, via subcutaneous (under the skin) injection per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC/MM Fusion Vaccine
Description: Dendritic Cell and tumor fusion vaccine, via subcutaneous (under the skin) injection per protocol.
Study: NCT06798740

Intervention type: DEVICE
Intervention: Sugita Titanium Aneurysm Clip II
Description: Aneurysm clipping is a surgical procedure used to treat brain aneurysms.
Study: NCT06794658

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: software
Description: Caaring is an electronic data collection notebook that allows patients to confidentially fill out data/questionnaires on their mobile phone and report them through an application that will be installed on the patient's mobile phone. Besides, This group (G_CAARING) will receive educational and prevention recommendations relative to diabetes.
Study: NCT06795503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cyclophosphamide
Description: Docetaxel (T) at a dose of 75 mg/m² was administered intravenously on Day 1 of each cycle, and Cyclophosphamide (C) at a dose of 600 mg/m² was administered intravenously on Day 1 of each cycle as well.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin, cyclophosphamide plus paclitaxel
Description: Patients in the control group received the EC-P regimen chemotherapy, with a cycle length of 21 days, for a total of 8 cycles. The specific treatment was as follows: Epirubicin (E) at a dose of 90 mg/m² and Cyclophosphamide (C) at a dose of 600 mg/m² were administered intravenously on Day 1 of each cycle for the first 4 cycles. This was followed by Paclitaxel (P) at a dose of 80 mg/m², administered intravenously on Days 1, 8, and 15 of each cycle for the subsequent 4 cycles.
Study: NCT06792942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nature view curtain group
Description: During the fine needle biopsy, the patient will look at the nature view curtain on the ceiling.
Study: NCT06796985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin
Description: Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm). Participants will receive this drug twice throughout the duration of the study. Approximately 200 units of botulinum neurotoxin will be administered per injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin
Description: Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm). Participants will receive this drug twice throughout the duration of the study. Approximately 200 units of botulinum neurotoxin will be administered per injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device
Description: A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management. The device will be used five times during the study. Each use will last approximately ten minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device
Description: A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management. The device will be used five times during the study. Each use will last approximately ten minutes.
Study: NCT06793709

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT06800027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SALSA group intervention: Going to lunch at the restaurant in a group and attending healthy eating workshops.
Description: The intervention group will dine at a selected and trained restaurant twice a week for 4 months (from March to June 2024). A facilitator will accompany the participants to the restaurant and supervise them. Once a month, a healthy habits and meal supplementation workshop will be held at the senior citizens' centre. Participants will not be required to pay for the meals at the restaurant or for participation in the workshops. The control group will receive standard care at their Primary Care Centre.~In order for the restaurant to provide appropriate services tailored to the users' needs, training will be conducted by professionals from the Alicia Foundation on how to manage the nutrition of elderly individuals and other participants in the study according to their dietary needs.
Study: NCT06799130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrument-assisted soft tissue mobilization
Description: instrument-assisted soft tissue mobilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: instrument-assisted soft tissue mobilization
Description: instrument-assisted soft tissue mobilization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrument-assisted soft tissue mobilization
Description: instrument-assisted soft tissue mobilization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy technique
Description: Muscle energy technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle energy technique
Description: Muscle energy technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy technique
Description: Muscle energy technique
Study: NCT06800222

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modern agents rehab
Description: rehabilitation interventions containing modern physical agents together with classical interventions

Intervention type: OTHER
Group type: OTHER
Intervention: classical rehab
Description: classical rehabilitation interventions
Study: NCT06798922

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard post-operative radiotherapy without flap sparing (current practice)
Description: Standard post-operative radiotherapy without flap sparing (current practice)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy with flap sparing
Description: Post-operative radiotherapy with flap sparing
Study: NCT06799325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acceptance and commitment therapy based stress management program
Description: The Stress Management Program Based on Acceptance and Commitment Therapy will be applied to the intervention group, consisting of 6 sessions, 1 session per week, and each session lasting 45 minutes.
Study: NCT06799039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Patients will be consecutively enrolled into one of five dosing including 1g, 2g, 5g, 7g and 9g.
Study: NCT06800157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: LW402
Description: Oral tablets administered BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: LW402
Description: Oral tablets administered BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Other: placebo
Description: Placebo to match LW402 administered BID
Study: NCT06799663

Intervention type: OTHER
Intervention: activity questionnaire
Description: Physical activity questionnaire will be applied on children and adolescents to compare the effect of smart phone on physical fitness

Intervention type: OTHER
Intervention: activity questionnaire
Description: Physical activity questionnaire will be applied on children and adolescents to compare the effect of smart phone on physical fitness

Intervention type: OTHER
Intervention: Raven's Progressive Matrices test (RPM)
Description: Raven's Progressive Matrices test will be applied on children and adolescents to compare the effect of smart phone on intelligence
Study: NCT05377450

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Engage Partial Knee
Description: Unicompartmental knee arthroplasty utilizing the Engage Partial Knee system without bone cement.
Study: NCT06799663

Intervention type: OTHER
Intervention: Raven's Progressive Matrices test (RPM)
Description: Raven's Progressive Matrices test will be applied on children and adolescents to compare the effect of smart phone on intelligence

Intervention type: OTHER
Intervention: Postural assessment software
Description: Postural assessment software will be applied on children and adolescents to compare the effect of smart phone on posture

Intervention type: OTHER
Intervention: Postural assessment software
Description: Postural assessment software will be applied on children and adolescents to compare the effect of smart phone on posture
Study: NCT06798948

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra
Description: Oral combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo maltodextrin
Description: The patient takes two tablets of the placebo maltodextrin every day
Study: NCT06800248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emodepside (BAY 44-4400)
Description: Treatment with single dose of oral 15 mg emodepside

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebendazole 100 MG
Description: Treatment with 100 mg mebendazole orally administered b.i.d. for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: similar placebo to mebendazole
Description: Treatment with mebendazole similar placebo orally administered b.i.d. for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: matching placebo of emodepside
Description: Treatment with single dose of oral emodepside matching placebo
Study: NCT06798363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: different dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: different dose
Study: NCT05576922

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic-surgical approach + autogenous graft
Description: Coronally advanced flap with an autogenous graft (CTG)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prosthetic-surgical approach + graft substitute
Description: Coronally advanced flap with a graft substitute (collagen matrix and rhPDGF-BB)